Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
Milgrom SA, Pinnix CC, Chuang H, Oki Y, Akhtari M, Mawlawi O, Garg N, Gunther JR, Reddy JP, Smith GL, Rohren E, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Abou Yehia Z, Fanale M, Dabaja BS. Milgrom SA, et al. Among authors: garg n. Br J Haematol. 2017 Nov;179(3):488-496. doi: 10.1111/bjh.14902. Epub 2017 Aug 18. Br J Haematol. 2017. PMID: 28832956 Free PMC article.
Primary Osteosarcoma of the Breast: Pathophysiology and Imaging Review.
Mujtaba B, Nassar SM, Aslam R, Garg N, Madewell JE, Taher A, Hanafy AK, Whitman G. Mujtaba B, et al. Among authors: garg n. Curr Probl Diagn Radiol. 2020 Mar-Apr;49(2):116-123. doi: 10.1067/j.cpradiol.2019.01.001. Epub 2019 Jan 3. Curr Probl Diagn Radiol. 2020. PMID: 30655112 Review.
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Burger JA, et al. Among authors: garg n. Lancet Oncol. 2014 Sep;15(10):1090-9. doi: 10.1016/S1470-2045(14)70335-3. Epub 2014 Aug 20. Lancet Oncol. 2014. PMID: 25150798 Free PMC article. Clinical Trial.
Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement.
Christopherson K, Lei X, Barcenas C, Buchholz TA, Garg N, Hoffman KE, Kuerer HM, Mittendorf E, Perkins G, Shaitelman SF, Smith GL, Stauder M, Strom EA, Tereffe W, Woodward WA, Smith BD. Christopherson K, et al. Among authors: garg n. Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):574-581. doi: 10.1016/j.ijrobp.2019.02.049. Epub 2019 Mar 6. Int J Radiat Oncol Biol Phys. 2019. PMID: 30851348 Free PMC article.
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Jain N, et al. Among authors: garg n. Leukemia. 2021 Dec;35(12):3421-3429. doi: 10.1038/s41375-021-01280-8. Epub 2021 May 18. Leukemia. 2021. PMID: 34007049 Clinical Trial.
1,545 results